JP2015535257A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535257A5 JP2015535257A5 JP2015539868A JP2015539868A JP2015535257A5 JP 2015535257 A5 JP2015535257 A5 JP 2015535257A5 JP 2015539868 A JP2015539868 A JP 2015539868A JP 2015539868 A JP2015539868 A JP 2015539868A JP 2015535257 A5 JP2015535257 A5 JP 2015535257A5
- Authority
- JP
- Japan
- Prior art keywords
- syndrome
- usher
- pharmaceutically acceptable
- acceptable salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *c1c(c(-c2ccccc2)n[n]2)c2nnc1-*1ccccc1 Chemical compound *c1c(c(-c2ccccc2)n[n]2)c2nnc1-*1ccccc1 0.000 description 6
- HSJQUSKVXNPUON-UHFFFAOYSA-N Cc1n[n](C)c2nnc(-c3ccccc3)c(Cl)c12 Chemical compound Cc1n[n](C)c2nnc(-c3ccccc3)c(Cl)c12 HSJQUSKVXNPUON-UHFFFAOYSA-N 0.000 description 1
- HTZBLVQITYMELR-UHFFFAOYSA-N Cc1n[n](CCO)c2c1c(Cl)c(-c1ccccc1)nn2 Chemical compound Cc1n[n](CCO)c2c1c(Cl)c(-c1ccccc1)nn2 HTZBLVQITYMELR-UHFFFAOYSA-N 0.000 description 1
- FSEOFLSWKQOKJB-UHFFFAOYSA-N OCC[n](c1nnc(-c2ccccc2)c(Cl)c11)nc1-c1cccnc1 Chemical compound OCC[n](c1nnc(-c2ccccc2)c(Cl)c11)nc1-c1cccnc1 FSEOFLSWKQOKJB-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718611P | 2012-10-25 | 2012-10-25 | |
| US61/718,611 | 2012-10-25 | ||
| US201361775402P | 2013-03-08 | 2013-03-08 | |
| US61/775,402 | 2013-03-08 | ||
| PCT/US2013/066939 WO2014066836A1 (en) | 2012-10-25 | 2013-10-25 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015535257A JP2015535257A (ja) | 2015-12-10 |
| JP2015535257A5 true JP2015535257A5 (enExample) | 2016-12-15 |
| JP6291502B2 JP6291502B2 (ja) | 2018-03-14 |
Family
ID=50545356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539868A Active JP6291502B2 (ja) | 2012-10-25 | 2013-10-25 | ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2911671B1 (enExample) |
| JP (1) | JP6291502B2 (enExample) |
| AU (1) | AU2013334139B2 (enExample) |
| CA (1) | CA2889494C (enExample) |
| ES (1) | ES2687854T3 (enExample) |
| HU (1) | HUE039970T2 (enExample) |
| IL (1) | IL238288B (enExample) |
| PL (1) | PL2911671T3 (enExample) |
| WO (1) | WO2014066836A1 (enExample) |
| ZA (1) | ZA201502655B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2701510T3 (pl) | 2011-04-25 | 2017-07-31 | Usher Iii Initiative Inc | Pirazolopirydazyny oraz sposoby leczenia zwyrodnieniowych chorób siatkówki i utraty słuchu związanych z zespołem ushera |
| US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| TR201816028T4 (tr) * | 2012-10-25 | 2018-11-21 | Usher Iii Initiative Inc | Pirazolopiridazinler ve retinal-dejeneratif hastalıkların ve Usher Sendromu ile ilişkili işitme kaybının tedavi edilmesine yönelik yöntemler. |
| WO2017045955A1 (en) * | 2015-09-14 | 2017-03-23 | Basf Se | Heterobicyclic compounds |
| JP7376471B2 (ja) | 2017-06-05 | 2023-11-08 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| KR20210005559A (ko) | 2018-03-27 | 2021-01-14 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
| SMT202400286T1 (it) | 2018-06-27 | 2024-09-16 | Ptc Therapeutics Inc | Composti eterociclici ed eteroarilici per il trattamento della corea di huntington |
| AU2019294482B2 (en) | 2018-06-27 | 2022-09-01 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| WO2020161209A1 (en) | 2019-02-06 | 2020-08-13 | Syngenta Crop Protection Ag | Herbicidal fused pyridazine compounds |
| WO2020161208A1 (en) | 2019-02-06 | 2020-08-13 | Syngenta Crop Protection Ag | Herbicidal fused pyridazine compounds |
| EP4466264A1 (en) * | 2022-01-19 | 2024-11-27 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Geralexin and uses thereof for the treatment of retinal degenerative diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206723D0 (en) * | 2002-03-21 | 2002-05-01 | Glaxo Group Ltd | Novel compounds |
| WO2007075911A2 (en) * | 2005-12-22 | 2007-07-05 | Yale University | Inhibition of glycogen synthase kinase and methods of treating autoimmune or immune inflammatory disease |
| WO2009062118A2 (en) * | 2007-11-07 | 2009-05-14 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| PL2701510T3 (pl) * | 2011-04-25 | 2017-07-31 | Usher Iii Initiative Inc | Pirazolopirydazyny oraz sposoby leczenia zwyrodnieniowych chorób siatkówki i utraty słuchu związanych z zespołem ushera |
| TR201816028T4 (tr) * | 2012-10-25 | 2018-11-21 | Usher Iii Initiative Inc | Pirazolopiridazinler ve retinal-dejeneratif hastalıkların ve Usher Sendromu ile ilişkili işitme kaybının tedavi edilmesine yönelik yöntemler. |
-
2013
- 2013-10-25 AU AU2013334139A patent/AU2013334139B2/en active Active
- 2013-10-25 PL PL13848995T patent/PL2911671T3/pl unknown
- 2013-10-25 HU HUE13848995A patent/HUE039970T2/hu unknown
- 2013-10-25 CA CA2889494A patent/CA2889494C/en active Active
- 2013-10-25 EP EP13848995.0A patent/EP2911671B1/en active Active
- 2013-10-25 WO PCT/US2013/066939 patent/WO2014066836A1/en not_active Ceased
- 2013-10-25 JP JP2015539868A patent/JP6291502B2/ja active Active
- 2013-10-25 ES ES13848995.0T patent/ES2687854T3/es active Active
-
2015
- 2015-04-14 IL IL238288A patent/IL238288B/en active IP Right Grant
- 2015-04-20 ZA ZA2015/02655A patent/ZA201502655B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015535257A5 (enExample) | ||
| JP2017186358A5 (enExample) | ||
| JP2016518328A5 (enExample) | ||
| JP2018024682A5 (enExample) | ||
| JP2018024670A5 (enExample) | ||
| JP2017515901A5 (enExample) | ||
| JP2015518008A5 (enExample) | ||
| JP2021502388A5 (enExample) | ||
| JP2016106149A5 (enExample) | ||
| JP2017537066A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2012107057A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2012092103A5 (enExample) | ||
| EP4643945A3 (en) | Neuroactive steroids and methods of use thereof | |
| JP2011518833A5 (enExample) | ||
| JP2016006053A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2016130266A5 (enExample) | ||
| JP2015199738A5 (enExample) | ||
| EP4241772A3 (en) | Process for the preparation of compounds useful for treating spinal muscular atrophy | |
| JP2017509586A5 (enExample) | ||
| JP2009545527A5 (enExample) | ||
| JP2010511721A5 (enExample) | ||
| JP2018521020A5 (enExample) |